Top

Pediatric Drugs

Published in:

01-06-2009 | Therapy In Practice

Pediatric Generalized Anxiety Disorder

Epidemiology, Diagnosis, and Management

Authors: Dr Courtney Pierce Keeton, Amie C. Kolos, John T. Walkup

Published in: Pediatric Drugs | Issue 3/2009

Abstract

Pediatric generalized anxiety disorder (GAD) is characterized by excessive and uncontrollable worry about a variety of events and is accompanied by physical symptoms such as headaches, tension, restlessness, gastrointestinal distress, and heart palpitations. Symptoms impose marked distress and interfere with social, emotional, and educational functioning. GAD occurs in over 10% of children and adolescents, has an average age of onset of 8.5 years, and is more often reported in girls. Common co-occurring conditions include separation anxiety disorder and social phobia.

Assessment involves a multi-informant, multi-method approach involving the child, parents, and school teachers. A clinical interview should be conducted to assess for the three primary ways anxiety presents: behaviors, thoughts, and somatic symptoms. Several semi-structured diagnostic interviews are available, and the Anxiety Disorders Interview Schedule is increasingly used. Rating scales completed by the patient, caregivers, and teachers provide useful information for diagnosis and symptom monitoring. Several scales are available to assess patients for the Diagnostic and Statistical Manual of Mental Disorders (4th Edition) GAD diagnosis; however, instruments generally cannot distinguish children with GAD from children with similar anxiety disorders.

Both cognitive-behavioral therapy (CBT) and selective serotonin reuptake inhibitors (SSRIs) have demonstrated efficacy for the treatment of pediatric anxiety disorders including GAD. Evidence suggests that the combination of CBT plus sertraline offers additional benefit compared with either treatment alone. With pharmacotherapy, systematic tracking of treatment-emergent adverse events such as headaches, stomach aches, behavioral activation, worsening symptoms, and emerging suicidal thoughts is important. Recommended starting doses are fluvoxamine 25mg/day, fluoxetine 10mg/day, and sertraline 25mg/day, though lower starting doses are possible. Dosing can be adjusted as often as weekly with the goal of achieving a high-quality response, while minimizing side effects. Long-term treatment with medication has not been well studied; however, to achieve optimal long-term outcome extended use of medication may be required. It is recommended to continue medication for approximately 1 year following remission in symptoms, and when discontinuing medication to choose a stress-free time of the year. If symptoms return, medication re-initiation should be considered seriously.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994

Silverman WK, Eisen AR. Age differences in the reliability of parent and child reports of child anxious symptomatology using a structured interview. J Am Acad Child Adolesc Psychiatry 1992; 31(1): 117–24PubMedCrossRef

Beidel DC. Social phobia and overanxious disorder in school-age children. J Am Acad Child Adolesc Psychiatry 1991; 30(4): 545–52PubMedCrossRef

Kendall PC, Warman MJ. Anxiety disorders in youth: diagnostic consistency across DSM-III-R and DSM-IV. J Anxiety Disord 1996; 10(6): 452–63CrossRef

Costello EJ, Egger HL, Angold A. The developmental epidemiology of anxiety disorders: phenomenology, prevalence, and comorbidity. Child Adolesc Psychiatr Clin N Am 2005; 14(4): 631–48PubMedCrossRef

Breslau J, Aguilar-Gaxiola S, Kendler KS, et al. Specifying race-ethnic differences in risk for psychiatric disorder in a USA national sample. Psychol Med 2006; 36(1): 57–68PubMedCrossRef

Lewinsohn PM, Gotlib IH, Lewinsohn M, et al. Gender differences in anxiety disorders and anxiety symptoms in adolescents. J Abnorm Psychol 1998; 107(1): 109–17PubMedCrossRef

Masi G, Millepiedi S, Mucci M, et al. Generalized anxiety disorder in referred children and adolescents. J Am Acad Child Adolesc Psychiatry 2004; 43(6): 752–60PubMedCrossRef

Pine DS. Research review: a neuroscience framework for pediatric anxiety disorders. J Child Psychol Psychiatry 2007; 48(7): 631–48PubMedCrossRef

10.

Vasey MW, Dadds MR. An introduction to the developmental psycho-pathology of anxiety. In: Vasey MW, Dadds MR, editors. The developmental psychopathology of anxiety. New York: Oxford University Press, 2001: 3–26

11.

Ialongo N, Edelsohn G, Werthamer-Larsson L, et al. The significance of self-reported anxious symptoms in first-grade children. J Abnorm Child Psychol 1994; 22(4): 441–55PubMedCrossRef

12.

Chavira DA, Stein MB, Bailey K, et al. Child anxiety in primary care: prevalent but untreated. Depress Anxiety 2004; 20(4): 155–64PubMedCrossRef

13.

Masi G, Mucci M, Favilla L, et al. Symptomatology and comorbidity of generalized anxiety disorder in children and adolescents. Compr Psychiatry 1999; 40(3): 210–5PubMedCrossRef

14.

Verduin TL, Kendall PC. Differential occurrence of comorbidity within childhood anxiety disorders. J Clin Child Adolesc Psychol 2003; 32(2): 290–5PubMedCrossRef

15.

Birmaher B, Axelson DA, Monk K, et al. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 2003; 42(4): 415–23PubMedCrossRef

16.

The Research Units on Pediatric Psychopharmacology Anxiety Study Group (RUPP). Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 2001; 344(17): 1279–85CrossRef

17.

Blair K, Shaywitz J, Smith BW, et al. Response to emotional expressions in generalized social phobia and generalized anxiety disorder: evidence for separate disorders. Am J Psychiatry 2008; 165(9): 1193–202PubMedCrossRef

18.

Pine DS, Cohen P, Gurley D, et al. The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders. Arch Gen Psychiatry 1998; 55(1): 56–64PubMedCrossRef

19.

Gould RA, Otto MW, Pollack MH, et al. Cognitive behavioral and pharmacological treatment of generalized anxiety disorder: a preliminary meta-analysis. Behav Ther 1997; 28(2): 285–305CrossRef

20.

Research Units on Pediatric Psychopharmacology Anxiety Study Group. The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties. J Am Acad Child Adolesc Psychiatry 2002; 41(9): 1061–9CrossRef

21.

Moffitt TE, Caspi A, Harrington H, et al. Generalized anxiety disorder and depression: childhood risk factors in a birth cohort followed to age 32. Psychol Med 2007; 37(3): 441–52PubMedCrossRef

22.

Last CG, Perrin S, Hersen M, et al. A prospective study of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 1996; 35(11): 1502–10PubMedCrossRef

23.

Kaplow JB, Curran PJ, Angold A, et al. The prospective relation between dimensions of anxiety and the initiation of adolescent alcohol use. J Clin Child Psychol 2001; 30(3): 316–26PubMedCrossRef

24.

Sartor CE, Lynskey MT, Heath AC, et al. The role of childhood risk factors in initiation of alcohol use and progression to alcohol dependence. Addiction 2007; 102(2): 216–25PubMedCrossRef

25.

Connolly SD, Bernstein GA. Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry 2007; 46(2): 267–83PubMedCrossRef

26.

Grills AE, Ollendick TH. Multiple informant agreement and the anxiety disorders interview schedule for parents and children. J Am Acad Child Adolesc Psychiatry 2003; 42(1): 30–40PubMedCrossRef

27.

Schniering CA, Hudson JL, Rapee RM. Issues in the diagnosis and assessment of anxiety disorders in children and adolescents. Clin Psychol Rev 2000; 20(4): 453–78PubMedCrossRef

28.

Safford SM, Kendall PC, Flannery-Schroeder E, et al. A longitudinal look at parent-child diagnostic agreement in youth treated for anxiety disorders. J Clin Child Adolesc Psychol 2005; 34(4): 747–57PubMedCrossRef

29.

Wood JJ, McLeod BD, Sigman M, et al. Parenting and childhood anxiety: theory, empirical findings, and future directions. J Child Psychol Psychiatry 2003; 44(1): 134–51PubMedCrossRef

30.

Puliafico AC, Kendall PC. Threat-related attentional bias in anxious youth: a review. Clin Child Fam Psychol Rev 2006; 9(3): 162–80PubMedCrossRef

31.

Weems CF, Zakem AH, Costa NM, et al. Physiological response and childhood anxiety: association with symptoms of anxiety disorders and cognitive bias. J Clin Child Adolesc Psychol 2005; 34(4): 712–23PubMedCrossRef

32.

Ginsburg GS, Riddle MA, Davies M. Somatic symptoms in children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry 2006; 45(10): 1179–87PubMedCrossRef

33.

Hofflich SA, Hughes AA, Kendall PC. Somatic complaints and childhood anxiety disorders. Int J Clin Health Psychol 2006; 6(2): 229–42

34.

Kaufman J, Birmaher B, Brent DA, et al. The Schedule for Affective Disorders and Schizophrenia for School-Age Children: Present and Lifetime Version (version 1.0). Pittsburgh (PA): University of Pittsburgh School of Medicine, 1996

35.

Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997; 36(7): 980–8PubMedCrossRef

36.

March JS, Parker JDA, Sullivan K, et al. The Multidimensional Anxiety Scale for Children (MASC): factor structure, reliability, and validity. J Am Acad Child Adolesc Psychiatry 1997; 36(4): 554–65PubMedCrossRef

37.

Birmaher B, Brent DA, Chiappetta L, et al. Psychometric properties of the Screen for Child Anxiety Related Emotional Disorders (SCARED): a replication study. J Am Acad Child Adolesc Psychiatry 1999; 38(10): 1230–6PubMedCrossRef

38.

Muris P, Merckelbach H, Schmidt H, et al. The revised version of the Screen for Child Anxiety Related Emotional Disorders (SCARED-R): factor structure in normal children. Pers Individ Dif 1999; 26(1): 99–112CrossRef

39.

Muris P, Dreessen L, Bögels S, et al. A questionnaire for screening a broad range of DSM-defined anxiety disorder symptoms in clinically referred children and adolescents. J Child Psychol Psychiatry 2004; 45(4): 813–20PubMedCrossRef

40.

Spence SH. Structure of anxiety symptoms among children: a confirmatory factor-analytic study. J Abnorm Psychol 1997; 106(2): 280–97PubMedCrossRef

41.

Chorpita BF, Yim L, Moffitt C, et al. Assessment of symptoms of DSM-IV anxiety and depression in children: a revised child anxiety and depression scale. Behav Res Ther 2000; 38(8): 835–55PubMedCrossRef

42.

Baldwin JS, Dadds MR. Reliability and validity of parent and child versions of the multidimensional anxiety scale for children in community samples. J Am Acad Child Adolesc Psychiatry 2007; 46(2): 252–60PubMedCrossRef

43.

Rynn MA, Barber JP, Khalid-Khan S, et al. The psychometric properties of the MASC in a pediatric psychiatric sample. J Anxiety Disord 2006; 20(2): 139–57PubMedCrossRef

44.

Dierker LC, Albano AM, Clarke GN, et al. Screening for anxiety and depression in early adolescence. J Am Acad Child Adolesc Psychiatry 2001; 40(8): 929–36PubMedCrossRef

45.

Wood JJ, Piacentini JC, Bergman RL, et al. Concurrent validity of the anxiety disorders section of the Anxiety Disorders Interview Schedule for DSM-IV: child and parent versions. J Clin Child Adolesc Psychol 2002; 31(3): 335–42PubMed

46.

Birmaher B, Khetarpal S, Brent D, et al. The Screen for Child Anxiety Related Emotional Disorders (SCARED): scale construction and psychometric characteristics. J Am Acad Child Adolesc Psychiatry 1997; 36(4): 545–53PubMedCrossRef

47.

Muris P, Merckelbach H, Mayer B, et al. The Screen for Child Anxiety Related Emotional Disorders (SCARED) and traditional childhood anxiety measures. J Behav Ther Exp Psychiatry 1998; 29(4): 327–39PubMedCrossRef

48.

Wren FJ, Berg EA, Heiden LA, et al. Childhood anxiety in a diverse primary care population: parent-child reports, ethnicity and SCARED factor structure. J Am Acad Child Adolesc Psychiatry 2007; 46: 332–40PubMedCrossRef

49.

Spence SH, Barrett PM, Turner CM. Psychometric properties of the Spence Children’s Anxiety Scale with young adolescents. J Anxiety Disord 2003; 17(6): 605–25PubMedCrossRef

50.

Nauta MH, Scholing A, Rapee RM, et al. A parent-report measure of children’s anxiety: psychometric properties and comparison with child-report in a clinic and normal sample. Behav Res Ther 2004; 42(7): 813–39PubMedCrossRef

51.

Spence SH. A measure of anxiety symptoms among children. Behav Res Ther 1998; 36(5): 545–66PubMedCrossRef

52.

Chorpita BF, Moffitt CE, Gray J. Psychometric properties of the Revised Child Anxiety and Depression Scale in a clinical sample. Behav Res Ther 2005; 43(3): 309–22PubMedCrossRef

53.

Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med 2008; 359(26): 2753–66PubMedCrossRef

54.

Langley AK, Bergman RL, McCracken J, et al. Impairment in childhood anxiety disorders: preliminary examination of the child anxiety impact scale-parent version. J Child Adolesc Psychopharmacol 2004; 14(1): 105–14PubMedCrossRef

55.

Muris P, Merckelbach H, Ollendick TH, et al. What is the Revised Fear Survey Schedule for Children measuring? Behav Res Ther 2002 11; 40(11): 1317–26PubMedCrossRef

56.

Velting ON, Setzer NJ, Albano AM. Update on and advances in assessment and cognitive-behavioral treatment of anxiety disorders in children and adolescents. Prof Psychol Res Pr 2004; 35(1): 42–54CrossRef

57.

Myers K, Winters NC. Ten-year review of rating scales: II. Scales for internalizing disorders. J Am Acad Child Adolesc Psychiatry 2002; 41(6): 634–59PubMedCrossRef

58.

Ginsburg GS, Siqueland L, Masia-Warner C, et al. Anxiety disorders in children: Family matters. Cogn Behav Pract 2004; 11(1): 28–43CrossRef

59.

Brown AM, Deacon BJ, Abramowitz JS, et al. Parents’ perceptions of pharmacological and cognitive-behavioral treatments for childhood anxiety disorders. Behav Res Ther 2007; 45(4): 819–28PubMedCrossRef

60.

Merikangas KR. Vulnerability factors for anxiety disorders in children and adolescents. Child Adolesc Psychiatr Clin N Am 2005; 14(4): 649–79PubMedCrossRef

61.

Keller MB, Lavori PW, Wunder J, et al. Chronic course of anxiety disorders in children and adolescents. J Am Acad Child Adolesc Psychiatry 1992; 31(4): 595–9PubMedCrossRef

62.

Kendall PC. Treating anxiety disorders in children: results of a randomized clinical trial. J Consult Clin Psychol 1994; 62(1): 100–10PubMedCrossRef

63.

Kendall PC, Flannery-Schroeder E, Panichelli-Mindel SM, et al. Therapy for youths with anxiety disorders: a second randomized clincal trial. J Consult Clin Psychol 1997; 65(3): 366–80PubMedCrossRef

64.

King NJ, Heyne D, Ollendick TH. Cognitive-behavioral treatments for anxiety and phobic disorders in children and adolescents: a review. Behav Disord 2005; 30(3): 241–57

65.

Compton SN, McKnight CD, March JS. Combining medication and psychosocial treatments: an evidence-based medicine approach. New York: Guilford Press, 2004

66.

Gould RA, Buckminster S, Pollack MH, et al. Cognitive-behavioral and pharmacological treatment for social phobia: a meta-analysis. Clin Psychol Sci Pract 1997; 4(4): 291–306CrossRef

67.

Durham RC, Chambers JA, MacDonald RR, et al. Does cognitive-behavioural therapy influence the long-term outcome of generalized anxiety disorder? An 8–14 year follow-up of two clinical trials. Psychol Med 2003; 33(3): 499–509PubMedCrossRef

68.

Ishikawa S, Okajima I, Matsuoka H, et al. Cognitive behavioural therapy for anxiety disorders in children and adolescents: a meta-analysis. Child Adolesc Ment Health 2007; 12(4): 164–72CrossRef

69.

Kendall PC. Cognitive-behavioral therapy for anxious children: therapist manual. 2nd ed. Ardmore (PA): Workbook Publishing, 2000

70.

Gosch EA, Flannery-Schroeder E, Mauro CF, et al. Principles of cognitive-behavioral therapy for anxiety disorders in children. J Cogn Psychother 2006; 20(3): 247–62CrossRef

71.

Kendall PC, Treadwell KRH. Cognitive-behavioral treatment for childhood anxiety disorders. Washington, DC: American Psychological Association, 1996

72.

Bouchard S, Mendlowitz SL, Coles ME, et al. Considerations in the use of exposure with children. Cogn Behav Pract 2004; 11(1): 56–65CrossRef

73.

Kendall PC, Braswell L. Medical applications of cognitive-behavioral interventions with children. J Dev Behav Pediatr 1986; 7(4): 257–64PubMedCrossRef

74.

Grover RL, Hughes AA, Bergman RL, et al. Treatment modifications based on childhood anxiety diagnosis: demonstrating the flexibility in manualized treatment. J Cogn Psychother 2006; 20(3): 275–86CrossRef

75.

Birmaher B, Waterman GS, Ryan N, et al. Fluoxetine for childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 1994; 33(7): 993–9PubMedCrossRef

76.

Compton SN, Grant PJ, Chrisman AK, et al. Sertraline in children and adolescents with social anxiety disorder: an open trial. J Am Acad Child Adolesc Psychiatry 2001; 40(5): 564–71PubMedCrossRef

77.

Dummit III ES, Klein RG, Tancer NK, et al. Fluoxetine treatment of children with selective mutism: an open trial. J Am Acad Child Adolesc Psychiatry 1996; 35(5): 615–21PubMedCrossRef

78.

Reinblatt SP, Riddle MA. The pharmacological management of childhood anxiety disorders: a review. Psychopharmacology (Berl) 2007; 191(1): 67–86CrossRef

79.

Rynn MA, Siqueland L, Rickels K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry 2001; 158(12): 2008–14PubMedCrossRef

80.

Rynn MA, Riddle MA, Yeung PP, et al. Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. Am J Psychiatry 2007; 164(2): 290–300PubMedCrossRef

81.

Simeon JG, Ferguson HB, Knott V, et al. Clinical, cognitive, and neuro-physiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders. J Am Acad Child Adolesc Psychiatry 1992; 31(1): 29–33PubMedCrossRef

82.

Bridge J, Iyengar S, Salary C, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007; 297(15): 1683–96PubMedCrossRef

83.

Clark DB, Birmaher B, Axelson D, et al. Fluoxetine for the treatment of childhood anxiety disorders: open-label, long-term extension to a controlled trial. J Am Acad Child Adolesc Psychiatry 2005; 44(12): 1263–70PubMedCrossRef

84.

Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54: 1031–7PubMedCrossRef

85.

Brady K, Pearstein T, Asnis GM, et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA 2000; 283: 1837–44PubMedCrossRef

86.

March JS, Biederman J, Wolkow R, et al. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial [published erratum appears in JAMA 2000; 283: 1293] JAMA 1998; 280: 1752–6PubMedCrossRef

87.

Bernstein GA, Borchardt CM, Perwien AR, et al. Imipramine plus cognitive-behavioral therapy in the treatment of school refusal. J Am Acad Child Adolesc Psychiatry 2000; 39(3): 276–83PubMedCrossRef

88.

Gittelman-Klein R, Klein DF. Controlled imipramine treatment of school phobia. Arch Gen Psychiatry 1971; 25: 204–7CrossRef

89.

Klein RG, Koplewicz HS, Kanner A. Imipramine treatment of children with separation anxiety disorder. J Am Acad Child Adolesc Psychiatry 1992; 31(1): 21–8PubMedCrossRef

90.

Bernstein GA, Borchardt CM, Perwien AR. Anxiety disorders in children and adolescents: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1996; 35(9): 1110–9PubMedCrossRef

91.

Bernstein GA, Hektner JM, Borchardt CM, et al. Treatment of school refusal: one-year follow-up. J Am Acad Child Adolesc Psychiatry 2001; 40(2): 206–13PubMedCrossRef

92.

Roberts R, Rodriguez W, Murphy D, et al. Pediatric drug labeling: improving the safety and efficacy ofpediatric therapies. JAMA 2003; 290(7): 905–11PubMedCrossRef

93.

March JS, Entusah AR, Rynn M, et al. A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biol Psychiatry 2007; 62(10): 1149–54PubMedCrossRef

94.

Wagner KD, Berard R, Stein MB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 2004; 61(11): 1153–62PubMedCrossRef

95.

Zito JM, Safer DJ, DosReis S, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med 2003; 157(1): 17–25PubMedCrossRef

96.

Libby AM, Brent DA, Morrato EH, et al. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry 2007; 164(6): 884–91PubMedCrossRef

97.

Nemeroff CB, Kalali A, Keller MB, et al. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry 2007; 64(4): 466–72PubMedCrossRef

98.

Rosack J. New data show declines in antidepressant prescribing. Psychiatr News 2005; 40(17): 1–39

99.

Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006; 63(3): 332–9PubMedCrossRef

100.

US FDA. Revisions to medication guide [online]. Available from URL: http://www.fda.gov/cder/drug/antidepressants/antidepressants_MG_2007.pdf [Accessed 2007 Jul 15]

101.

Walkup J, Labellarte M. Current thinking: complications of SSRI treatment. J Child Adolesc Psychopharmacol 2001; 11(1): 1–4PubMedCrossRef

102.

Rynn MA, Brawman-Mintzer O. Generalized anxiety disorder: acute and chronic treatment. CNS Spectr 2004; 9(10): 716–23PubMed

103.

Weintrob N, Cohen D, Klipper-Aurbach Y, et al. Decreased growth during therapy with selective serotonin reuptake inhibitors. Arch Pediatr Adolesc Med 2002; 156(7): 696–701PubMed

104.

Safer DJ, Zito JM. Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. J Child Adolesc Psychopharmacol 2006; 16(1): 159–69PubMedCrossRef

105.

Martin A, Young C, Leckman JF, et al. Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med 2004; 158(8): 773–80PubMedCrossRef

106.

Reinblatt SP, Riddle MA. Selective serotonin reuptake inhibitor-induced apathy: a pediatric case series. J Child Adolesc Psychopharmacol 2006; 16(1): 227–33PubMedCrossRef

107.

Garland EJ, Baerg EA. A motivational syndrome associated with selective serotonin reuptake inhibitors in children and adolescents. J Child Adolesc Psychopharmacol 2001; 11(2): 181–6PubMedCrossRef

108.

Yuan Y, Tsoi K, Hunt RH. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding? Am J Med 2006; 119(9): 719–27PubMedCrossRef

109.

Lake MB, Birmaher B, Wassick S, et al. Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence. J Child Adolesc Psychopharmacol 2000; 10(1): 35–48PubMedCrossRef

110.

Pine DS. Treating children and adolescents with selective serotonin reuptake inhibitors: how long is appropriate? J Child Adolesc Psychopharmacol 2002; 12(3): 189–203PubMedCrossRef

Title: Pediatric Generalized Anxiety Disorder
Epidemiology, Diagnosis, and Management
Authors: Dr Courtney Pierce Keeton
Amie C. Kolos
John T. Walkup
Publication date: 01-06-2009
Publisher: Springer International Publishing
Published in: Pediatric Drugs / Issue 3/2009
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI: https://doi.org/10.2165/00148581-200911030-00003

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Pediatric Generalized Anxiety Disorder

Epidemiology, Diagnosis, and Management

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2009

The Dutch Medicines for Children Research Network

Current Pharmacological Management of Gastro-Esophageal Reflux in Children

Atomoxetine

Multimodal Treatments versus Pharmacotherapy Alone in Children with Psychiatric Disorders